NeuroDerm Ltd.

NeuroDerm Ltd. is a biopharmaceutical company focused on developing innovative drug-device combination therapies for central nervous system disorders, particularly Parkinson's disease. Founded in 2003 and headquartered in Rehovot, Israel, NeuroDerm specializes in drug-device combination solutions for Parkinson's disease. The company was involved in an IPO in November 2014, raising USD 45.

00 mn, effectively marking a pivotal moment in its business strategy and operations. CEO Kengo Isshiki leads the firm, which has engaged in a total of 3 deals since inception, with its last deal occurring on November 14, 2014. NeuroDerm specializes in developing innovative drug-device combination solutions, primarily targeting central nervous system disorders, with a particular emphasis on Parkinson's disease. Their flagship product, ND0612, is a proprietary formulation of levodopa/carbidopa designed for continuous subcutaneous delivery, which aims to address motor fluctuations in Parkinson's patients.

This user-friendly system includes a compact and portable infusion pump that allows for self-administration, thereby enhancing patient autonomy. NeuroDerm's products are geared toward improving the quality of life for patients and their families by reducing the disease burden associated with Parkinson's. The company's solutions are currently undergoing late-stage development and are intended for markets in North America and Europe, aligning with regulatory approvals from the U. S.

Food and Drug Administration (FDA) and the European Medicines Agency (EMA). NeuroDerm's revenue is primarily derived from the commercialization of its flagship product, ND0612, once it receives necessary approvals and enters the market. The company has established a framework for transactions that includes partnerships with pharmaceutical firms, healthcare providers, and potentially direct sales to consumers. These transactions are expected to be structured as B2B engagements, where healthcare institutions and pharmacies facilitate access to NeuroDerm's therapies for patients.

The pricing plans for ND0612 are anticipated to reflect its status as a next-generation treatment for Parkinson's disease, focusing on the value it provides in managing symptoms and improving patient outcomes. Revenue generation will be contingent on the successful introduction of their products into the healthcare marketplace, supported by strategic marketing and distribution efforts. NeuroDerm aims to expand its product line and market presence significantly. The recent IPO in November 2014, which raised USD 45.

00 mn, will be pivotal in advancing their late-stage development of ND0612 and supporting marketing efforts. The company plans to introduce ND0612 into new markets in North America and Europe, pending regulatory approval, which is crucial for their growth strategy. NeuroDerm is focused on enhancing its drug-device combinations to further address unmet needs in Parkinson’s disease management.